Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma

INTRODUCTION: Anaplastic lymphoma kinase (ALK) fusion mutation is more common in younger and never-smoking lung cancer patients. The association of smoking and ALK-tyrosine kinase inhibitors (TKIs) on overall survival (OS) of treatment-naïve ALK-positive advanced lung adenocarcinoma remains unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhe-Rong, Ku, Hsiu-Ying, Chen, Kun-Chieh, Chiang, Chun-Ju, Wang, Chih-Liang, Chen, Chih-Yi, Tsai, Chun-Ming, Huang, Ming-Shyan, Yu, Chong-Jen, Chen, Jin-Shing, Chou, Teh-Ying, Lee, Wen-Chung, Wang, Chun-Chieh, Liu, Tsang-Wu, Hsia, Jiun-Yi, Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064125/
https://www.ncbi.nlm.nih.gov/pubmed/37007097
http://dx.doi.org/10.3389/fonc.2023.1063695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064125/
https://www.ncbi.nlm.nih.gov/pubmed/37007097
http://dx.doi.org/10.3389/fonc.2023.1063695

Ejemplares similares